Crizanlizumab
Modify Date: 2024-04-06 11:07:08
Crizanlizumab structure
|
Common Name | Crizanlizumab | ||
|---|---|---|---|---|
| CAS Number | 1690318-25-2 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CrizanlizumabCrizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease[1][2][3]. |
| Name | Crizanlizumab |
|---|
| Description | Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
P-selectin[2] |
| References |
[1]. Hannah A. Blair, et al. Crizanlizumab: First Approval. Drugs. 80, 79-84 (2020). |
| No Any Chemical & Physical Properties |